Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 11/20 | 0.46 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770328 | 1.00 | PTGER4 (0.52) | PTGER4SPHK1SPHK2L3MBTL1GLP1R | |
| SCHEMBL31140564 | 0.89 | PTGER4 (0.48) | PTGER4GLP1RACSS2 | |
| SCHEMBL29770353 | 0.88 | KDM4E (0.54) | PTGER4SPHK1SPHK2GLP1RACSS2 | |
| SCHEMBL30174466 | 0.88 | KDM4E (0.54) | PTGER4SPHK1SPHK2GLP1RACSS2 | |
| SCHEMBL28839348 | 0.88 | KDM4E (0.54) | PTGER4SPHK1SPHK2GLP1RACSS2 | |
| SCHEMBL28839349 | 0.88 | KDM4E (0.54) | PTGER4SPHK1SPHK2GLP1RACSS2 | |
| SCHEMBL25970931 | 0.87 | GLP1R (0.51) | PTGER4GLP1R | |
| SCHEMBL24529616 | 0.87 | GLP1R (0.51) | PTGER4GLP1R | |
| SCHEMBL30497392 | 0.86 | GLP1R (0.49) | PTGER4GLP1RPDE10A | |
| SCHEMBL23516961 | 0.86 | CNR2 (0.51) | PTGER4GLP1RACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330949-A | Polycyclic compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115461334-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114907351-A | Tricyclic GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PTGER4 431/4885SPHK1 1562/4885SPHK2 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.